title: Open letter to the FDA: new drug trials must be relevant.
authors.forename: F
authors.initials: F
authors.lastname: Vincenti
authors.forename: G
authors.initials: G
authors.lastname: Klintmalm
authors.forename: P F
authors.initials: PF
authors.lastname: Halloran
mesh_terms: D002986:Clinical Trials as Topic / Q000592:standards*; D004358:Drug Therapy / Q000592:standards*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D012307:Risk Factors; D014181:Transplantation Immunology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007166:Immunosuppressive Agents